Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
Abstract Diabetic kidney disease (DKD) is the major contributor to the mortality and the financial burden of diabetes, accounting for approximately 50% of the cases of end‐stage renal disease (ESRD) in the developed world. Several studies have already demonstrated that achieving blood pressure targe...
Main Authors: | Sebastian Niezen, Humberto Diaz del Castillo, Lumen A. Mendez Castaner, Alessia Fornoni |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-07-01
|
Series: | Endocrinology, Diabetes & Metabolism |
Subjects: | |
Online Access: | https://doi.org/10.1002/edm2.72 |
Similar Items
-
Study of antihyperglycaemic activity of medicinal plant extracts in alloxan induced diabetic rats
by: Anoja P Attanayake, et al.
Published: (2013-01-01) -
Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetes
by: Sinclair Alan J, et al.
Published: (2012-03-01) -
Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials
by: Gianluigi Savarese, et al.
Published: (2020-12-01) -
Prescribing Pattern of Oral Antihyperglycaemic Drugs, Rationality and Adherence to American Diabetes Association (ADA) Treatment Guidelines among Type 2 Diabetes Mellitus (T2DM) Postmenopausal Women
by: Sudhaa Sharma, et al.
Published: (2016-01-01) -
Design and synthesis of tricyclic terpenoid derivatives as novel PTP1B inhibitors with improved pharmacological property and in vivo antihyperglycaemic efficacy
by: Lingling Yang, et al.
Published: (2020-01-01)